Your browser is no longer supported. Please, upgrade your browser.
INSY INSYS Therapeutics, Inc. daily Stock Chart
INSYS Therapeutics, Inc.
Index- P/E- EPS (ttm)-1.60 Insider Own63.83% Shs Outstand69.21M Perf Week12.47%
Market Cap343.28M Forward P/E- EPS next Y-0.61 Insider Trans0.00% Shs Float26.81M Perf Month15.08%
Income-117.70M PEG- EPS next Q-0.25 Inst Own22.40% Short Float24.09% Perf Quarter-32.05%
Sales97.20M P/S3.53 EPS this Y-50.00% Inst Trans1.07% Short Ratio7.94 Perf Half Y-33.60%
Book/sh0.00 P/B- EPS next Y46.50% ROA-50.80% Target Price8.50 Perf Year-39.81%
Cash/sh1.45 P/C3.42 EPS next 5Y- ROE-362.00% 52W Range3.35 - 11.65 Perf YTD41.71%
Dividend- P/FCF- EPS past 5Y-28.50% ROI-335.90% 52W High-57.42% Beta2.24
Dividend %- Quick Ratio0.60 Sales past 5Y55.50% Gross Margin86.80% 52W Low48.06% ATR0.38
Employees343 Current Ratio0.70 Sales Q/Q-40.40% Oper. Margin- RSI (14)63.84 Volatility7.62% 9.82%
OptionableYes Debt/Eq0.00 EPS Q/Q82.00% Profit Margin- Rel Volume1.33 Prev Close4.78
ShortableYes LT Debt/Eq0.00 EarningsMar 07 AMC Payout- Avg Volume813.63K Price4.96
Recom2.00 SMA2021.26% SMA5015.09% SMA200-27.98% Volume1,081,723 Change3.77%
Dec-19-18Resumed Janney Buy
Mar-09-18Downgrade Piper Jaffray Neutral → Underweight
Oct-11-17Reiterated RBC Capital Mkts Outperform $14
Aug-04-17Reiterated RBC Capital Mkts Outperform $16 → $14
May-10-17Downgrade Piper Jaffray Overweight → Neutral
Dec-21-16Reiterated RBC Capital Mkts Outperform $23 → $16
Sep-22-16Reiterated RBC Capital Mkts Outperform $32 → $26
Apr-12-16Reiterated Jefferies Buy $23 → $17
Apr-11-16Reiterated Piper Jaffray Overweight $46 → $28
Feb-24-16Reiterated Jefferies Buy $36 → $23
Feb-01-16Reiterated RBC Capital Mkts Outperform $49 → $44
Mar-09-15Reiterated RBC Capital Mkts Outperform $65 → $71
Mar-04-15Reiterated RBC Capital Mkts Outperform $57 → $65
Dec-15-14Reiterated RBC Capital Mkts Outperform $53 → $57
Nov-12-14Reiterated RBC Capital Mkts Outperform $51 → $53
Nov-12-14Downgrade Oppenheimer Outperform → Perform $40
Oct-02-14Initiated RBC Capital Mkts Outperform $51
Aug-14-13Reiterated Oppenheimer Outperform $23 → $27
Jul-31-13Initiated Oppenheimer Outperform $23
Feb-15-19 03:19PM  Opioid maker used rap video to push powerful painkiller Associated Press
12:59PM  Drug company used rap video to push for higher doses, sales Associated Press
09:04AM  Worst Performing Cannabis Stocks in 2018 Investopedia
Feb-14-19 07:32AM  Insys executives used rap video to push sales of potentially lethal opioid CBS News Videos
Feb-08-19 02:35PM  4 Marijuana Stocks Looking To Pick Up Speed This Month ACCESSWIRE +7.30%
Feb-07-19 11:44AM  Zynerba Stock Is Marijuana-Adjacent Play Worth a Look InvestorPlace
10:00AM  Cannabis Plays Going Higher ACCESSWIRE
Feb-05-19 11:20AM  4 Marijuana Stocks Looking to Set the Standard ACCESSWIRE +9.82%
10:34AM  Top Marijuana Stocks on the NASDAQ Investopedia
10:00AM  Playing the Big Cannabis Rebound ACCESSWIRE
08:51AM  The Only 2 Pot Stocks to Fall in January Motley Fool
08:30AM  Biotech Stocks to Watch ACCESSWIRE
Feb-01-19 01:02PM  Cannabis Company Surges After Winning the POT Ticker Lottery Yahoo Finance Video
Jan-30-19 08:19AM  Better Marijuana Stock Buy: Medical Marijuana Inc. vs. Insys Therapeutics Motley Fool
08:00AM  Biotechs You Need to Radar Now ACCESSWIRE
Jan-29-19 09:24PM  Insys executive gave doctor lap dance while promoting drug, witness says Reuters
06:42PM  Insys executive gave doctor lap dance while promoting drug, witness says Reuters
04:05PM  Insys executive gave doctor lap dance while promoting drug, witness says Reuters
03:54PM  Insys exec gave doctor lap dance while promoting drug, witness says Reuters
Jan-28-19 03:45PM  Prosecutor: Drug founder driven by greed in bribing doctors Associated Press -8.14%
03:09PM  'Greed' fuelled Insys founder's opioid bribe scheme - prosecutor Reuters
03:07PM  'Greed' fueled Insys founder's opioid bribe scheme -prosecutor Reuters
08:00AM  Biotech Stocks to Watch this Week ACCESSWIRE
06:00AM  Insys founder, former execs face opioid kickback scheme trial Reuters
Jan-25-19 08:48AM  Families hoping for justice from prescription bribes trial Associated Press
Jan-19-19 09:36AM  Janney: Cannabis, Naloxone, Adrenaline The Perfect Mix For Insys Benzinga
Jan-14-19 03:50PM  Here's Why Marijuana Stock Insys Therapeutics Fell More Than 63% in 2018 Motley Fool -5.78%
Jan-10-19 11:00AM  INSYS Therapeutics Rises on Dose-Ranging Allergy Study Data Zacks
Jan-09-19 04:36PM  Former Insys CEO pleads guilty to opioid kickback scheme Reuters
06:00AM  INSYS Therapeutics Announces Results of Dose-Finding PK Study for Epinephrine Nasal Spray for Treatment of Anaphylaxis GlobeNewswire
Jan-08-19 07:21AM  The 10 Worst-Performing Marijuana Stocks in 2018 Motley Fool
Jan-04-19 05:11PM  Which Biopharma Stocks Are Looking To Score Big In Cannabis Medicine? Investor's Business Daily
Jan-03-19 06:00AM  INSYS Therapeutics to Present at 37th Annual J.P. Morgan Healthcare Conference GlobeNewswire -6.44%
Dec-31-18 11:00AM  Cannabis Firms Set to Explode ACCESSWIRE
Dec-26-18 06:21PM  Ex-Insys CEO to plead guilty to opioid kickback scheme Reuters
Dec-24-18 08:21AM  2 Marijuana Stocks That Could Be Halved in 2019 Motley Fool
Dec-21-18 08:06AM  More Than 1.9 Million Californians May Own Pot Stocks Without Realizing It Motley Fool -11.33%
Dec-19-18 11:07AM  Analyst: Insys To Benefit As FDA Pushes Naloxone Access Benzinga
Dec-18-18 02:47PM  New Hampshire physician assistant guilty of Insys opioid kickback scheme Reuters -9.38%
08:07AM  INSYS announces Progress on Spray Technology Products, CBD Pharmaceuticals Market Exclusive
06:00AM  INSYS Therapeutics Announces Participation at FDA Advisory Committee Meeting Addressing the Co-Prescribing of Naloxone GlobeNewswire
Dec-17-18 06:00AM  INSYS Therapeutics Provides Update on Strategic Alterative Review Process and Product Pipeline Spanning Pharmaceutical Cannabinoids and Spray Technology GlobeNewswire
Dec-16-18 04:31PM  Surprise! The Largest U.S. Pension Fund Just Bought These 2 Marijuana Stocks Motley Fool
Dec-12-18 06:08PM  Opioid maker Insys paid kickbacks to physician assistant, jury hears Reuters
01:00PM  Opioid maker Insys paid physician assistant kickbacks, U.S. jury hears Reuters
06:00AM  Physician assistant faces U.S. trial over Insys opioid kickbacks Reuters
Dec-10-18 10:35AM  Alternatives to Watch ACCESSWIRE
Dec-06-18 07:55AM  Detailed Research: Economic Perspectives on AT&T, JD, EMC Insurance Group, Insys Therapeutics, Medidata Solutions, and Heritage-Crystal Clean What Drives Growth in Today's Competitive Landscape GlobeNewswire
Dec-05-18 08:21AM  These 17 Pot Stocks Were Throttled in November Motley Fool
Dec-04-18 11:48AM  INSYS Therapeutics Inc (NASDAQ:INSY): Time For A Financial Health Check Simply Wall St. -7.96%
06:00AM  INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy GlobeNewswire
Dec-03-18 05:27PM  Muddy Waters Research founder Carson Block talks morality shorts Yahoo Finance Video
Nov-28-18 08:55PM  Former Insys executive pleads guilty to opioid bribe scheme Reuters
08:37PM  Former Insys executive pleads guilty to opioid bribe scheme Reuters
03:54PM  Ex-executive to cooperate with feds in opioid kickback case Associated Press
03:51PM  Ex-executive to cooperate with feds in opioid kickback case Associated Press
12:10PM  Former Insys executive pleads guilty to opioid bribe scheme Reuters
11:21AM  Former Insys executive pleads guilty to opioid bribe scheme Reuters
08:21AM  3 Marijuana Stocks to Avoid Like the Plague in December Motley Fool
06:00AM  Former executive at opioid maker Insys to plead guilty Reuters
Nov-27-18 11:30AM  Cannabis Stocks That Could Uptrend ACCESSWIRE
Nov-21-18 02:25PM  Why Marijuana Stock INSYS Therapeutics Is Down 30% in 2018 Motley Fool
08:21AM  It's Time to Throw This Marijuana Stock Away and Never Look Back Motley Fool
Nov-20-18 09:52PM  Edited Transcript of INSY earnings conference call or presentation 5-Nov-18 10:00pm GMT Thomson Reuters StreetEvents
07:00AM  Clinical Data from Long-Term Safety-Study of Companys Pharmaceutical CBD in Refractory Pediatric Epilepsy To Be Presented at American Epilepsy Society Meeting GlobeNewswire
Nov-19-18 11:00AM  Company with Technology to Compete with Problematic Opioids ACCESSWIRE -5.35%
Nov-16-18 09:00AM  12 NYSE- And NASDAQ-Listed Stocks With Cannabis Exposure Benzinga
Nov-12-18 11:35AM  Cannabinoids and Other Pain Relief Options ACCESSWIRE
Nov-06-18 07:04AM  The Daily Biotech Pulse: EyePoint Licenses Eye Inflammation Drug, Insys Strategic Review Of Opioid Assets, Neos Offering Benzinga -11.61%
12:30AM  Insys Looks to Sell Opioid-Related Assets, Including Subsys The Wall Street Journal
Nov-05-18 07:00PM  Insys Therapeutics (INSY) Reports Q3 Loss, Lags Revenue Estimates Zacks
05:55PM  Insys Therapeutics: 3Q Earnings Snapshot Associated Press
04:16PM  INSYS Therapeutics Reports Third Quarter 2018 Results GlobeNewswire
04:15PM  INSYS Therapeutics to Assess Strategic Alternatives for Opioid-Related Assets GlobeNewswire
Nov-01-18 10:00AM  Oversold CBD Stocks ACCESSWIRE +5.39%
06:00AM  INSYS Therapeutics Announces Results of PK Study Assessing Proprietary Intranasal Naloxone Formulations versus Intramuscular and Intravenous Naloxone for Opioid Overdose GlobeNewswire
Oct-30-18 10:03AM  What's in Store for INSYS Therapeutics' (INSY) Q3 Earnings? Zacks +9.75%
Oct-29-18 08:55AM  Consolidated Research: 2018 Summary Expectations for Insys Therapeutics, Achaogen, Astec Industries, Central European Media Enterprises, Pzena Investment Management, and Clementia Pharmaceuticals Fundamental Analysis, Key Performance Indications GlobeNewswire
Oct-22-18 05:00PM  INSYS Therapeutics to Report Third Quarter 2018 Results on Nov. 5 GlobeNewswire -8.31%
Oct-21-18 11:27AM  As opioid crisis raged, Insys pushed higher doses of addictive drug and pushed salespeople to own doctors MarketWatch
Oct-18-18 12:00PM  Up and Coming Cannabis Company on a Roll ACCESSWIRE
Oct-12-18 06:00AM  INSYS Therapeutics and UC San Diegos Center for Medicinal Cannabis Research Add Anxiety in Anorexia Nervosa to Series of Collaborative Cannabidiol (CBD) Studies GlobeNewswire
Oct-10-18 05:35PM  Meet the Portland attorney defending opioid maker Insys against hundreds of lawsuits American City Business Journals
06:00AM  INSYS Therapeutics Names New General Counsel GlobeNewswire
Oct-01-18 10:32AM  2 Marijuana Biotechs to Watch InvestorPlace
06:00AM  INSYS Therapeutics Signs Definitive License Agreement with Lunatus to Commercialize SUBSYS® (fentanyl sublingual spray) in the Middle East GlobeNewswire
Sep-28-18 10:30AM  Stem Cell Companies Moving The Markets ACCESSWIRE
Sep-27-18 06:53PM  INSYS Therapeutics to Present at 2018 Cantor Global Healthcare Conference GlobeNewswire
Sep-24-18 06:00AM  INSYS Therapeutics Completes Initial Clinical Study of Dronabinol Inhalation with Innovative Breath-Actuated Inhaler GlobeNewswire
Sep-23-18 01:31PM  Better Buy: Insys Therapeutics, Inc. vs. GW Pharmaceuticals PLC Motley Fool
Sep-19-18 08:00AM  Today's Research Reports on Trending Tickers: Conatus Pharmaceuticals and INSYS Therapeutics ACCESSWIRE
Sep-18-18 10:30AM  Cannabis and Biotech Stocks That Could Skyrocket ACCESSWIRE +11.06%
Sep-14-18 02:00PM  INSYS Therapeutics to Present at Janney Healthcare Conference GlobeNewswire
01:17PM  Intriguing Cannabis and Biotech Firms ACCESSWIRE
Sep-13-18 11:29AM  City of Boston sues drugmakers over opioid epidemic American City Business Journals
Sep-11-18 03:06PM  Could INSYS Therapeutics Incs (NASDAQ:INSY) Investor Composition Impacts Your Returns? Simply Wall St.
Sep-06-18 04:50PM  Maryland charges opioid maker with major misconduct Associated Press -7.00%
01:53PM  Maryland charges Insys with engaging in deceptive opioid scheme Reuters
12:28PM  Maryland charges Insys engaged in deceptive opioid scheme Reuters
Sep-05-18 08:14PM  Here's Why INSYS Therapeutics, Inc. Jumped a Whopping 40.3% in August Motley Fool -5.94%
Insys Therapeutics, Inc., a specialty pharmaceutical company, develops and commercializes supportive care products. The company markets SUBSYS, a sublingual fentanyl spray for breakthrough cancer pain in opioid-tolerant adult patients; and SYNDROS, an orally administered liquid formulation of dronabinol for the treatment of chemotherapy-induced nausea and vomiting, and anorexia associated with weight loss in patients with AIDS. It is also developing Cannabidiol Oral Solution, which has completed pediatric study for the treatment of pediatric epilepsy; has completed Phase II study to treat west syndrome; and is in Phase II study for the treatment of childhood absence epilepsy, as well as Buprenorphine Sublingual Spray that has completed Phase III study to treat acute pain. In addition, the company is developing Cannabidiol Oral Solution for the treatment of prader willi; Buprenorphine/Naloxone Sublingual Spray to treat opioid dependence; and Naloxone Nasal Spray for the treatment of opioid antagonist. Insys Therapeutics, Inc. is headquartered in Chandler, Arizona.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Tambi BrianDirectorMay 10Option Exercise2.15162,504349,866166,504May 14 05:50 PM
Tambi BrianDirectorMay 10Sale6.41166,5041,067,2910May 14 05:50 PM